TrialCancer2011

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).

Athanassios Argiris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.